Influence of ABCC2 and ABCC4 polymorphisms on tenofovir plasma concentrations in Thai HIV-infected patients

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 6, 2015, Pages 3240-3245

  Rungtivasuwan, Kanokrat ^a   Avihingsanon, Anchalee ^a,b   Thammajaruk, Narukjaporn ^b   Mitruk, Siwaporn ^c   Burger, David M ^d   Ruxrungtham, Kiat ^a,b   Punyawudho, Baralee ^e   Pengsuparp, Thitima ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^c NAVAMINDRADHIRAJ UNIVERSITY   (Thailand)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e CHIANG MAI UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; RITONAVIR; TENOFOVIR; ABCC4 PROTEIN, HUMAN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2;

ADULT; AGE; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; DRUG BLOOD LEVEL; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GLOMERULUS FILTRATION RATE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; SEX; TREATMENT DURATION; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; GENETICS; GENOTYPING TECHNIQUE; HIV INFECTIONS; MIDDLE AGED;

ADULT; ANTI-HIV AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CROSS-SECTIONAL STUDIES; FEMALE; GENOTYPING TECHNIQUES; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; POLYMORPHISM, GENETIC; TENOFOVIR;

EID: 84929630582     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04930-14     Document Type: Article

References (26)

1. Kearney BP, Flaherty JF, Shah J. 2004. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet 43: 595-612. http://dx.doi.org/10.2165/00003088-200443090-00003.
2. Alvarez E, Morello J, Soriano V, Labarga P, Rodriguez-Novoa S. 2011. Critical appraisal and update on tenofovir in management of human immunodeficiency virus infection. Virus Adapt Treat 3:55-69. http://dx.doi.org/10.2147/VAAT.S12708.
3. Rodriguez-Novoa S, Labarga P, Soriano V. 2009. Pharmacogenetics of tenofovir treatment. Pharmacogenomics 10:1675-1685. http://dx.doi.org/10.2217/pgs.09.115.
4. Manosuthi W, Sukasem C, Thongyen S, Nilkamhang S, Sungkanuparph S. 2014. ABCC2∗1C and plasma tenofovir concentration are correlated to decreased glomerular filtration rate in patients receiving a tenofovir-containing antiretroviral regimen. J Antimicrob Chemother 69:2195-2201. http://dx.doi.org/10.1093/jac/dku129.
5. Kiser JJ, Aquilante CL, Anderson PL, King TM, Carten ML, Fletcher CV. 2008. Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients. J Acquir Immune Defic Syndr 47:298-303. http://dx.doi.org/10.1097/QAI.0b013e31815e7478.
6. Rodríguez-Nóvoa S, Labarga P, D'Avolio A, Barreiro P, Albalate M, Vispo E, Solera C, Siccardi M, Bonora S, Perri GD, Sariano V. 2010. Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. AIDS 24:1064-1066. http://dx.doi.org/10.1097/QAD.0b013e32833202e2.
7. Poizot-Martin I, Solas C, Allemand J, Obry-Roguet V, Pradel V, Bregigeon S, Faucher O, Lacarelle B. 2013. Renal impairment in patients receiving a tenofovir-cART regimen: impact of tenofovir trough concentration. J Acquir Immune Defic Syndr 62:375-380. http://dx.doi.org/10.1097/QAI.0b013e31827ce4ee.
8. Droste JA, Verweij-van Wissen CP, Kearney BP, Buffels R, Vanhorssen PJ, Hekster YA, Burger DM. 2005. Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers. Antimicrob Agents Chemother 49:680-684. http://dx.doi.org/10.1128/AAC.49.2.680-684.2005.
9. Kiser JJ, Carten ML, Aquilante CL, Anderson PL, Wolfe P, King TM, Delahunty T, Bushman LR. 2008. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther 83:265-272. http://dx.doi.org/10.1038/sj.clpt.6100269.
10. Izzedine H, Hulot JS, Villard E, Goyenvalle C, Dominguez S, Ghosn J, Valantin MA, Lechat P, Deray G. 2006. Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis 194:1481-1491. http://dx.doi.org/10.1086/508546.
11. Hagleitner MM, Coenen MJ, Schrauwen M, Vermeulen SH, deBont ES, Hoogerbrugge P, TeLoo DM. 2010. Association of a genetic variant in the ABCC2 gene with high methotrexate plasma concentrations in pediatric malignancies. J Clin Oncol 28:15s.
12. Anderson PL, Lamba J, Aquilante C, Schuetz E, Fletcher C. 2006. Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. J Acquir Immune Defic Syndr 42:441-449. http://dx.doi.org/10.1097/01.qai.0000225013.53568.69.
13. Hall AM. 2013. Update on tenofovir toxicity in the kidney. Pediatr Nephrol 28:1011-1023. http://dx.doi.org/10.1007/s00467-012-2269-7.
14. Ezinga M, Wetzels JF, Bosch ME, van der Ven AJ, Burger DM. 2014. Long-term treatment with tenofovir: prevalence of kidney tubular dysfunction and its association with tenofovir plasma concentration. Antivir Ther 19:765-771. http://dx.doi.org/10.3851/IMP2761.
15. Gagnieu M, Barkil ME, Livrozet JM, Cotte L, Miailhes P, Boibieux A, Guitton J, Tod M. 2008. Population pharmacokinetics of tenofovir in AIDS patients. J Clin Pharmacol 48:1282-1288. http://dx.doi.org/10.1177/0091270008322908.
16. Jullien V, Treluyer JM, Rey E, Jaffray P, Krivine A, Moachon L, Louet AL, Lescoat A, Dupin N, Salmon D, Pons G, Urien S. 2005. Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy. Antimicrob Agents Chemother 49:3361-3366. http://dx.doi.org/10.1128/AAC.49.8.3361-3366.2005.
17. Baxi SM, Greenblatt RM, Bacchetti P, Scherzer R, Minkoff H, Huang Y, Anastos K, Cohen M, Gange SJ, Young M, Shlipak MG, Gandhi M. 2014. Common clinical conditions - age, low BMI, ritonavir use, mild renal impairment - affect tenofovir pharmacokinetics in a large cohort of HIV-infected women. AIDS 28:59-66. http://dx.doi.org/10.1097/QAD.0000000000000033.
18. Rodriguez-Novoa S, Labarga P, Soriano V, Egan D, Albalater M, Morello J, Cuenca L, Gonzalez-Pardo G, Khoo S, Back D, Owen A. 2009. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis 48:e108-e116. http://dx.doi.org/10.1086/598507.
19. James AM, Ofotokun I, Sheth A, Acosta EP, King JR. 2012. Tenofovir: once-daily dosage in the management of HIV infection. Clin Med Insights Ther 4:201-216. http://dx.doi.org/10.4137/CMT.S8316.
20. Kearney BP, Mathias A, Mittan A, Sayre J, Ebrahimi R, Cheng AK. 2006. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J Acquir Immune Defic Syndr 43:278-283. http://dx.doi.org/10.1097/01.qai.0000243103.03265.2b.
21. Gutmann H, Fricker G, Drewe J, Toeroek M, Miller DS. 1999. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol Pharmacol 56:383-389.
22. Tong L, Phan TK, Robinson KL, Babusis D, Strab R, Bhoopathy S, Hidalgo IJ, Rhodes GR, Ray AS. 2007. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob Agents Chemother 51:3498-3504. http://dx.doi.org/10.1128/AAC.00671-07.
23. Fujita T, Brown C, Carlson EJ, Taylor T, Cruz M, Johns SJ, Stryke D, Kawamoto M, Fujita K, Castro R, Chen C, Lin ET, Brett CM, Burchard EG, Ferrin TE, Huang CC, Leabman MK, Giacomini KM. 2005. Functional analysis of polymorphisms in the organic anion transporter, SLC22A6 (OAT1). Pharmacogenet Genomics 15:201-209. http://dx.doi.org/10.1097/01213011-200504000-00003.
24. Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, Takane H, Irie S, Kusuhara H, Urasaki Y, Urae A, Higuchi S, Otsubo K, Sugiyama Y. 2003. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 73:554-565. http://dx.doi.org/10.1016/S0009-9236(03)00060-2.
25. Vormfelde SV, Schirmer M, Hagos Y, Toliat MR, Engelhardt S, Meineke I, Burckhardt G, Nurnnerg P, Brockmoller J. 2006. Torsemide renal clearance and genetic variation in luminal and basolateral organic anion transporters. Br J Clin Pharmacol 62:323-335. http://dx.doi.org/10.1111/j.1365-2125.2006.02655.x.
26. German P, Liu HC, Szwarcberg J, Hepner M, Andrews J, Kearney BP, Mathias A. 2012. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. J Acquir Immune Defic Syndr 61:32-40. http://dx.doi.org/10.1097/QAI.0b013e3182645648.